ADC Therapeutics SA (ADCT) Reports Q3 Loss of $0.29/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business Highlights
November 12, 2020 7:00 AM EST- Submitted BLA for lead program, Lonca, for treatment of relapsed or refractory DLBCL on September 21, 2020
- Commercial launch activities on track for potential U.S. launch of Lonca in mid-2021
- Initiated Phase 3 confirmatory trial of Lonca in combination with rituximab in second-line DLBCL
- Strong balance sheet with $494 million in cash and cash equivalents as of September 30, 2020 after completing an upsized follow-on public offering in September 2020
- Company to host conference call today at 8:30 a.m. ET
LAUSANNE,... More
